A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis

This study is testing a new biologic drug called vixarelimab in people with moderate to severe active ulcerative colitis (UC) — a chronic inflammatory bowel disease causing colon inflammation. Vixarelimab works by blocking specific proteins involved in the inflammatory process. **You may be eligible if...** - You have been diagnosed with UC for at least 3 months - Your UC is currently moderately to severely active - You have tried and failed standard treatments (such as steroids, immunosuppressants) or more advanced therapies (biologics or small molecule drugs) **You may NOT be eligible if...** - You have Crohn's disease or a type of colitis that is uncertain - There is suspicion of ischemic colitis, radiation colitis, microscopic colitis, or infectious colitis - You have had your colon surgically removed - You have previously been treated with JAK inhibitors (a class of drugs that suppress the immune system) Talk to your doctor to see if this trial is right for you.